ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¿¹Ãø ¹× ºÐ¼®(-2028³â) : Áö¿ªº°, Á¦Ç°º°, ÀýÂ÷º°, ÃÖÁ¾ »ç¿ëÀÚº°
North America Structural Heart Market Forecast to 2028 - Regional Analysis - by Product, Procedure, and End User
ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå(Structural Heart) ½ÃÀåÀº 2022³â 69¾ï 6,750¸¸ ´Þ·¯¿¡¼ 2028³â 112¾ï 147¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2022³âºÎÅÍ 2028³â±îÁöÀÇ CAGRÀº 8.2%·Î ÃßÁ¤µË´Ï´Ù.
Çõ½ÅÀûÀÎ ±¸Á¶Àû ½ÉÀå ¼ºñ½ºÀÇ °¡¿ë¼ºÀº ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀ» µÞ¹Þħ
¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ½ÉÇ÷°ü ÁúȯÀº Àü ¼¼°è »ç¸Á ¿øÀÎ 2À§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼ ½ÉÇ÷°ü ÁúȯÀ» °ü¸®Çϱâ À§ÇØ ´Ù¾çÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ½ÉÀå ÆÇ¸· ÁúȯÀº ½ÉºÎÀüÀÇ °¡Àå ÈçÇÑ ¿øÀÎ Áß Çϳª·Î ¿¹»óµË´Ï´Ù. ´ëµ¿¸Æ ÆÇ¸·°ú ½Â¸ðÆÇ¸·ÀÇ ÅðÇ༺ Áúȯ, »ï÷ÆÇ¸· ±â´É Àå¾Ö ÁúȯÀº ½ÉÇÑ °æ¿ì ÀÓ»ó °æ°ú¸¦ ¾ÇȽÃŵ´Ï´Ù. ÃÖ±Ù ±¸Á¶Àû ½ÉÀå Áúȯ¿¡ ´ëÇÑ ÃÖ¼Ò Ä§½ÀÀû, ¿Ü°úÀû, Ä«Å×ÅÍ ±â¹Ý ÁßÀç¼úÀÌ ±Þ°ÝÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±¸Á¶Àû ½ÉÀåÀº ½ÉÀå ÆÇ¸· ¼ö¼ú°ú °æÇÇÀû Ä«Å×ÅÍ ½Ã¼ú·Î ±¸¼ºµÈ ÁøÈÇÏ´Â ºÐ¾ß·Î, ½ÉÀå¿Ü°ú Àü¹®ÀÇ¿Í ³»°ú Àǻ縦 À§ÇÑ ´Ù¾çÇÑ ±³À° ÇÁ·Î±×·¥ÀÌ ¸¶·ÃµÇ°í ÀÖ½À´Ï´Ù. Áö³ 10³â µ¿¾È ±¸Á¶Àû ½ÉÀå ÁúȯÀÇ ¹ßº´·üÀÌ ±ÞÁõÇÔ¿¡ µû¶ó ÀηÂÀÇ ÀûÀýÇÑ ¿ª·®À» È®º¸Çϱâ À§ÇÑ °ø½ÄÀûÀÎ ±³À° ÇÁ·Î±×·¥ÀÇ °³¹ßÀÌ ÇÊ¿äÇØÁ³½À´Ï´Ù. ±³À°ÀÇ ±¸Á¶, ±â°£, ¹üÀ§´Â ÇÁ·Î±×·¥¸¶´Ù Å©°Ô ´Ù¸¨´Ï´Ù. ´ëºÎºÐÀÇ ÇÁ·Î±×·¥Àº °æÇÇÀû ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR)¿¡ ´ëÇÑ È®½ÇÇÑ ³ëÃâÀ» Á¦°øÇÏ´Â µ¿½Ã¿¡ ½É¹æÁß°Ý ¶Ç´Â ½É½ÇÁß°Ý °á¼Õ Æó¼â¼ú, ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â¼ú, ¼±Ãµ¼º ½ÉÀå °á¼Õ ÁßÀç¼ú¿¡ ´ëÇÑ ´ú ´Ù¾çÇÏ°í ´Ù¾çÇÑ °æÇèÀ» Á¦°øÇÕ´Ï´Ù. °æÇÇÀû ½Â¸ðÆÇ¸· ġȯ¼ú(TAVR), MitraClip ½Â¸ðÆÇ¸· ¼ö¸® ½Ã½ºÅÛ(Abbott Vascular), ÁÂ½É¹æ ºÎ¼Ó±â Æó»ö¼ú(LAAO) ½Ã¼úÀÇ µîÀåÀ¸·Î º¹ÀâÇÑ ½ÉÇ÷°ü ÁúȯÀ» °¡Áø ȯÀÚ¸¦ Ä¡·áÇϱâ À§ÇØ ½ÃÇàµÇ´Â ±¸Á¶Àû ½ÉÀå ½Ã¼úÀÇ ¾çÀÌ Å©°Ô Áõ°¡Çß½À´Ï´Ù. ¸¹Àº ±â°ü¿¡¼ À¯ÀԵǴ ȯÀÚ¸¦ ¼ö¿ëÇϱâ À§ÇØ ±¸Á¶Àû ½ÉÀå ÇÁ·Î±×·¥À» À§ÇÑ Ã¼°èÀûÀÎ Çü½ÄÀÇ ¼ºñ½º ¹× ½Ã¼úÀ» °³¹ßÇß½À´Ï´Ù. SHD ¼ö·ÃÀº Àü¹ÝÀûÀ¸·Î Èï¹Ì·Ó°í µµÀüÀûÀÌ¸ç º¸¶÷ ÀÖ´Â °úÁ¤ÀÔ´Ï´Ù. ÀÌ ºÐ¾ß°¡ ¹ßÀüÇÔ¿¡ µû¶ó ÃÖ°íÀÇ È¯ÀÚ Ä¡·á ǰÁúÀ» º¸ÀåÇϱâ À§ÇØ SHD ±³À°ÀÇ Ç¥ÁØÈ°¡ ¸Å¿ì Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ¾Õ¼ ¼³¸íÇÑ ¼ö¸¹Àº °í·Á »çÇ×À» Ž»öÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ´Â ¸àÅ並 ã´Â °ÍÀº ±³À°¿¡¼ ½Ç¹«·Î ¼º°øÀûÀ¸·Î ÀüȯÇÏ´Â µ¥ °¡Àå Å« ÀÚ»êÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå °³¿ä
ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº 2022³âºÎÅÍ 2028³â±îÁö CAGR 8.2%·Î ÃßÀÌÇÏ¸ç ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº Çõ½ÅÀûÀÎ ±¸Á¶Àû ½ÉÀå ¼ºñ½º, ½ÉÇ÷°ü Áúȯ ¼ö ¹× ÈÆ·Ã ÇÁ·Î±×·¥ Áõ°¡ÀÔ´Ï´Ù. ±×·¯³ª ±¸Á¶Àû ½ÉÀå Àåºñ¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦°¡ °è¼ÓµÇ´Â Ä¡·áÀÇ ³ôÀº ºñ¿ëÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÏ´Â ÁÖ¿ä ¿äÀÎÀÌ µÇ¾ú½À´Ï´Ù.
2028³â±îÁö ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(±Ý¾×)
ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀÇ ¼¼ºÐÈ
ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº Á¦Ç°, ÀýÂ÷, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.
Á¦Ç°º°·Î ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº Æó»ö±â, ȯÇü ¼ºÇü ¸µ, ½ÉÀå ÆÇ¸· dz¼± µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼ Æó»ö±â ºÎ¹®Àº °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÀýÂ÷º°·Î º¸¸é ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº ½ÉÀå ÆÇ¸· ÇùÂøÁõ, ½ÉÀå ÆÇ¸· ¿ª·ùÁõ, ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â ºÎÀüÁõÀ¸·Î ±¸ºÐµË´Ï´Ù. ½ÉÀå ÆÇ¸· ÇùÂøÁõ ºÎ¹®Àº 2022³â ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº°·Î º¸¸é ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2022³â ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹Àº 2022³â ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomedica Industry, Commerce and Representations Ltd, Micro Interventional Devices Inc´Â ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ±â¾÷ÀÇ ÀϺÎÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå- ÁÖ¿ä Æ÷ÀÎÆ®
Á¦3Àå Á¶»ç ¹æ¹ý
- Á¶»ç ¹üÀ§
- 2Â÷ Á¶»ç
- 1Â÷ Á¶»ç
Á¦4Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå-½ÃÀå »óȲ
- °³°ü
- PEST ºÐ¼®
- Àü¹®°¡ÀÇ °ßÇØ
Á¦5Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå-ÁÖ¿ä ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø ¿äÀÎ
- Çõ½ÅÀûÀÎ ±¸Á¶Àû ½ÉÀå ¼ºñ½ºÀÇ °¡¿ë¼º
- ½ÉÇ÷°ü Áúȯ Áõ·Ê Áõ°¡¿Í Æ®·¹ÀÌ´× ÇÁ·Î±×·¥
- ÁÖ¿ä ½ÃÀå ¼ºÀå ¾ïÁ¦ ¿äÀÎ
- ¼ö¼úºñ¿ë »ó½Â
- ±¸Á¶Àû ½ÉÀå ÀåÄ¡¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
- ÁÖ¿ä ½ÃÀå ±âȸ
- ±¸Á¶Àû ½ÉÀå¿¡¼ ÀΰøÁö´ÉÀÇ ÀÌ¿ë È®´ë
- ÇâÈÄ µ¿Çâ
- ±¸Á¶Àû ½ÉÀå µð¹ÙÀ̽º ºÐ¾ß¿¡¼ ±â¼úÀÇ Áøº¸
- ¿µÇ⠺м®
Á¦6Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå-ºÏ¹Ì ºÐ¼®
- ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¿¹Ãø ¹× ºÐ¼®
Á¦7Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : Á¦Ç°º°
- ±¸Á¶Àû ½ÉÀåÀÇ °³¿ä
- ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå : ¼öÀÍ Á¡À¯À², Á¦Ç°º°(2021³â, 2028³â)
- Æó»ö±â
- ȯ»ó ¼ºÇü ¸µ
- ½ÉÀå ÆÇ¸· dz¼±
- ±âŸ
Á¦8Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ÀýÂ÷º°
- ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå : ¼öÀÍ Á¡À¯À², ÀýÂ÷º°(2021³â, 2028³â)
- ½ÉÀåÆÇ ÇùÂøÁõ
- ½ÉÀå ÆÇ¸· ¿ª·ù
- ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â ºÎÀüÁõ
Á¦9Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ÃÖÁ¾ »ç¿ëÀÚº°
- ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå : ¼öÀÍ Á¡À¯À², ÃÖÁ¾ »ç¿ëÀÚº°(2021³â, 2028³â)
- º´¿ø
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- ½ÉÀå¼¾ÅÍ
Á¦10Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ±¹°¡º° ºÐ¼®
- ºÏ¹Ì : ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå
Á¦11Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå : »ê¾÷ Á¤¼¼
Á¦12Àå ±â¾÷ °³¿ä
- Abbott Laboratories
- Medtronic Plc
- Boston Scientific Corp
- Artivion Inc
- Edwards Lifesciences Corp
- Lepu Medical Technology Beijing Co Ltd
- Braile Biomedica Industry, Commerce and Representations Ltd
- Micro Interventional Devices Inc
Á¦13Àå ºÎ·Ï
LYJ
The North America structural heart market is expected to grow from US$ 6,967.50 million in 2022 to US$ 11,201.47 million by 2028. It is estimated to grow at a CAGR of 8.2% from 2022 to 2028.
Availability of Innovative Structural Heart Services Fuel North America Structural Heart Market
According to the World Health Organization (WHO), cardiovascular diseases are the second leading cause of death worldwide. Therefore, various initiatives are being taken to control cardiovascular diseases. Heart valve disease is expected to be one of the most common causes of heart failure. Degenerative diseases of aortic and mitral valves, and diseases of dysfunctional tricuspid valves lead to a worse clinical course in severe cases. Minimally invasive, surgical, and catheter-based interventions for structural heart disease have increased dramatically recently. The structural heart is an evolving field consisting of heart valve surgeries and transcatheter procedures; therefore, various training programs are being arranged for cardiac surgeons and physicians. Over the past decade, the burgeoning incidence of structural heart disease has necessitated the development of formal training programs to ensure the appropriate competency of workforces. The structure, length, and scope of training vary greatly between programs. Most programs provide solid exposure on transcatheter aortic valve replacement (TAVR) procedures, simultaneously providing a lesser and variable experience of atrial septal or ventricular septal defect closure, left atrial appendage closure, and congenital heart defect interventions. With the advent of TAVR, the MitraClip mitral valve repair system (Abbott Vascular), and left atrial appendage occlusion (LAAO) procedures, there has been a significant increase in the volume of structural cardiac procedures performed for treating patients with complex cardiovascular conditions. Many organizations have developed services and procedural offerings in an organized format for the structural cardiac program to accommodate the influx of patients. Training in SHD is exciting, challenging, and rewarding overall. As the field evolves, standardization of SHD training becomes extremely important to ensure the best quality of patient care. Finding a mentor to help navigate the numerous considerations outlined can be the best asset to successfully transitioning from training to practice.
North America Structural Heart Market Overview
The North America Structural heart market is estimated to grow at a CAGR of 8.2% from 2022 to 2028. Key factors driving the market growth are innovative structural heart services and rise in the number of cardiovascular diseases and training programs. However, high cost of procedure followed by stringent regulations regarding structure heart device are the major factor hampering the growth of the market.
North America Structural Heart Market Revenue and Forecast to 2028 (US$ Million)
North America Structural Heart Market Segmentation
The North America structural heart market is segmented into product, procedure, end user, and country.
Based on product, the North America structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held the largest share of the North America structural heart market in 2022.
Based on procedure, the North America structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held the largest share of the North America structural heart market in 2022.
Based on end user, the North America structural heart market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment held the largest share of the North America structural heart market in 2022.
Based on country, the North America structural heart market is segmented into US, Canada, and Mexico. US dominated the North America structural heart market in 2022.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomedica Industry, Commerce and Representations Ltd, and Micro Interventional Devices Inc are some of the leading companies operating in the North America structural heart market.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America structural heart market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in North America structural heart market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table Of Contents
1. Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.2.1 North America Structural Heart Market - by Product
- 1.2.2 North America Structural Heart Market - by Procedure
- 1.2.3 North America Structural Heart Market - by End User
- 1.2.4 North America Structural Heart Market - by Country
2. North America Structural Heart Market - Key Takeaways
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. North America Structural Heart Market - Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
- 4.3 Expert's Opinion
5. North America Structural Heart Market - Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Availability of Innovative Structural Heart Services
- 5.1.2 Rising Number of Cardiovascular Disease Cases and Training Programs
- 5.2 Key Market Restraints
- 5.2.1 High Cost of Procedures
- 5.2.2 Stringent Regulations Regarding Structure Heart Devices
- 5.3 Key Market Opportunities
- 5.3.1 Growing Use of Artificial Intelligence in Structural Heart
- 5.4 Future Trends
- 5.4.1 Technological Advancements in the Field of Structural Heart Devices
- 5.5 Impact analysis
6. North America Structural Heart Market -North America Analysis
- 6.1 North America Structural Heart Market Revenue Forecast and Analysis
7. North America Structural Heart Market - Revenue and Forecast to 2028 - by Product
- 7.1 Overview
- 7.2 North America Structural Heart Market Revenue Share, by Product 2021 & 2028 (%)
- 7.3 Occluders
- 7.3.1 Overview
- 7.3.2 Occluders: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4 Annuloplasty Rings
- 7.4.1 Overview
- 7.4.2 Annuloplasty Rings: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 7.5 Heart Valve Balloons
- 7.5.1 Overview
- 7.5.2 Heart Valve Balloons: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
8. North America Structural Heart Market - Revenue and Forecast to 2028 - by Procedure
- 8.1 Overview
- 8.2 North America Structural Heart Market Revenue Share, by Procedure 2021 & 2028 (%)
- 8.3 Heart Valve Stenosis
- 8.3.1 Overview
- 8.3.2 Heart Valve Stenosis: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 8.4 Heart Valve Regurgitation
- 8.4.1 Overview
- 8.4.2 Heart Valve Regurgitation: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 8.5 Left Atrial Appendage Closure
- 8.5.1 Overview
- 8.5.2 Left Atrial Appendage Closure: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
9. North America Structural Heart Market - Revenue and Forecast to 2028 - by End User
- 9.1 Overview
- 9.2 North America Structural Heart Market Revenue Share, by End User 2021 & 2028 (%)
- 9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 Hospitals: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 9.5 Cardiac Centers
- 9.5.1 Overview
- 9.5.2 Cardiac Centers: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
10. North America Structural Heart Market - Revenue and Forecast to 2028 -Country Analysis
- 10.1 North America: North America Structural Heart Market
- 10.1.1 Overview
- 10.1.1.1 United States: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.1.1 Overview
- 10.1.1.1.2 United States: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.1.3 United States: North America Structural Heart Market , by Product, 2019-2028 (US$ Million)
- 10.1.1.1.4 United States: North America Structural Heart Market , by Procedure, 2019-2028 (US$ Million)
- 10.1.1.1.5 United States: North America Structural Heart Market , by Heart Valve Stenosis Procedure, 2019-2028 (US$ Million)
- 10.1.1.1.6 United States: North America Structural Heart Market , by Heart Valve Regurgitation Procedure, 2019-2028 (US$ Million)
- 10.1.1.1.7 United States: North America Structural Heart Market , by End User, 2019-2028 (US$ Million)
- 10.1.1.2 Canada: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.2.1 Overview
- 10.1.1.2.2 Canada: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.2.3 Canada: North America Structural Heart Market , by Product, 2019-2028 (US$ Million)
- 10.1.1.2.4 Canada: North America Structural Heart Market , by Procedure, 2019-2028 (US$ Million)
- 10.1.1.2.5 Canada: North America Structural Heart Market , by Heart Valve Stenosis Procedure, 2019-2028 (US$ Million)
- 10.1.1.2.6 Canada: North America Structural Heart Market , by Heart Valve Regurgitation Procedure, 2019-2028 (US$ Million)
- 10.1.1.2.7 Canada: North America Structural Heart Market , by End User, 2019-2028 (US$ Million)
- 10.1.1.3 Mexico: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.3.1 Overview
- 10.1.1.3.2 Mexico: North America Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.3.3 Mexico: North America Structural Heart Market , by Product, 2019-2028 (US$ Million)
- 10.1.1.3.4 Mexico: North America Structural Heart Market , by Procedure, 2019-2028 (US$ Million)
- 10.1.1.3.5 Mexico: North America Structural Heart Market , by Heart Valve Stenosis Procedure, 2019-2028 (US$ Million)
- 10.1.1.3.6 Mexico: North America Structural Heart Market , by Heart Valve Regurgitation Procedure, 2019-2028 (US$ Million)
- 10.1.1.3.7 Mexico: North America Structural Heart Market , by End User, 2019-2028 (US$ Million)
11. North America Structural Heart Market -Industry Landscape
- 11.1 Overview
- 11.2 Growth Strategies
12. Company Profiles
- 12.1 Abbott Laboratories
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Medtronic Plc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Boston Scientific Corp
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Artivion Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Edwards Lifesciences Corp
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Lepu Medical Technology Beijing Co Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Braile Biomedica Industry, Commerce and Representations Ltd
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Micro Interventional Devices Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
13. Appendix
- 13.1 About the Insight Partners
- 13.2 Glossary of Terms